A prospective trial to evaluate the safety and efficacy of pravastatin for the treatment of refractory chronic graft-versus-host disease

Akiko Hori, Yoshinobu Kanda, Susumu Goyama, Yasushi Onishi, Yukiko Komeno, Kinuko Mitani, Yukiko Kishi, Seishi Ogawa, Osamu Imataki, Shigeru Chiba, Rie Kojima, Tamae Hamaki, Michiyo Sakiyama, Masahiro Kami, Atsushi Makimoto, Ryuji Tanosaki, Yoichi Takaue, Hisamaru Hirai

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

This prospective study evaluates the safety and efficacy of pravastatin for the treatment of chronic graft-versus-host disease (GVHD). We included 18 patients with refractory chronic GVHD. Oral pravastatin was started at 10 mg/day, and the dose was increased up to 40 mg/day in 4 weeks. This maximum dose was administered over 8 weeks. There were no severe adverse events caused by pravastatin. A clinical response was observed in the skin score in two patients, mouth score in five patients, eye score in two patients, liver score in three patients, platelet count score in one patient, and weight loss in two patients. The overall response rate was 28%. Immunophenotypic analyses showed that T-helper (Th) 1 cells were dominant in all but one patient before treatment and that the Th1/Th2 ratio tended to be lower in the responders than in the nonresponders. A randomized controlled trial is warranted to evaluate the efficacy of pravastatin against chronic GVHD.

Original languageEnglish
Pages (from-to)372-374
Number of pages3
JournalTransplantation
Volume79
Issue number3
DOIs
Publication statusPublished - 2005 Feb 15
Externally publishedYes

Fingerprint

Pravastatin
Graft vs Host Disease
Safety
Th1 Cells
Platelet Count
Mouth
Weight Loss
Randomized Controlled Trials
Prospective Studies
Skin
Liver

Keywords

  • Chronic graft-versus-host disease
  • Pravastatin
  • Treatment

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

A prospective trial to evaluate the safety and efficacy of pravastatin for the treatment of refractory chronic graft-versus-host disease. / Hori, Akiko; Kanda, Yoshinobu; Goyama, Susumu; Onishi, Yasushi; Komeno, Yukiko; Mitani, Kinuko; Kishi, Yukiko; Ogawa, Seishi; Imataki, Osamu; Chiba, Shigeru; Kojima, Rie; Hamaki, Tamae; Sakiyama, Michiyo; Kami, Masahiro; Makimoto, Atsushi; Tanosaki, Ryuji; Takaue, Yoichi; Hirai, Hisamaru.

In: Transplantation, Vol. 79, No. 3, 15.02.2005, p. 372-374.

Research output: Contribution to journalArticle

Hori, A, Kanda, Y, Goyama, S, Onishi, Y, Komeno, Y, Mitani, K, Kishi, Y, Ogawa, S, Imataki, O, Chiba, S, Kojima, R, Hamaki, T, Sakiyama, M, Kami, M, Makimoto, A, Tanosaki, R, Takaue, Y & Hirai, H 2005, 'A prospective trial to evaluate the safety and efficacy of pravastatin for the treatment of refractory chronic graft-versus-host disease', Transplantation, vol. 79, no. 3, pp. 372-374. https://doi.org/10.1097/01.TP.0000151001.64189.1D
Hori, Akiko ; Kanda, Yoshinobu ; Goyama, Susumu ; Onishi, Yasushi ; Komeno, Yukiko ; Mitani, Kinuko ; Kishi, Yukiko ; Ogawa, Seishi ; Imataki, Osamu ; Chiba, Shigeru ; Kojima, Rie ; Hamaki, Tamae ; Sakiyama, Michiyo ; Kami, Masahiro ; Makimoto, Atsushi ; Tanosaki, Ryuji ; Takaue, Yoichi ; Hirai, Hisamaru. / A prospective trial to evaluate the safety and efficacy of pravastatin for the treatment of refractory chronic graft-versus-host disease. In: Transplantation. 2005 ; Vol. 79, No. 3. pp. 372-374.
@article{f1b78890c3d64634a752b35b06885e14,
title = "A prospective trial to evaluate the safety and efficacy of pravastatin for the treatment of refractory chronic graft-versus-host disease",
abstract = "This prospective study evaluates the safety and efficacy of pravastatin for the treatment of chronic graft-versus-host disease (GVHD). We included 18 patients with refractory chronic GVHD. Oral pravastatin was started at 10 mg/day, and the dose was increased up to 40 mg/day in 4 weeks. This maximum dose was administered over 8 weeks. There were no severe adverse events caused by pravastatin. A clinical response was observed in the skin score in two patients, mouth score in five patients, eye score in two patients, liver score in three patients, platelet count score in one patient, and weight loss in two patients. The overall response rate was 28{\%}. Immunophenotypic analyses showed that T-helper (Th) 1 cells were dominant in all but one patient before treatment and that the Th1/Th2 ratio tended to be lower in the responders than in the nonresponders. A randomized controlled trial is warranted to evaluate the efficacy of pravastatin against chronic GVHD.",
keywords = "Chronic graft-versus-host disease, Pravastatin, Treatment",
author = "Akiko Hori and Yoshinobu Kanda and Susumu Goyama and Yasushi Onishi and Yukiko Komeno and Kinuko Mitani and Yukiko Kishi and Seishi Ogawa and Osamu Imataki and Shigeru Chiba and Rie Kojima and Tamae Hamaki and Michiyo Sakiyama and Masahiro Kami and Atsushi Makimoto and Ryuji Tanosaki and Yoichi Takaue and Hisamaru Hirai",
year = "2005",
month = "2",
day = "15",
doi = "10.1097/01.TP.0000151001.64189.1D",
language = "English",
volume = "79",
pages = "372--374",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - A prospective trial to evaluate the safety and efficacy of pravastatin for the treatment of refractory chronic graft-versus-host disease

AU - Hori, Akiko

AU - Kanda, Yoshinobu

AU - Goyama, Susumu

AU - Onishi, Yasushi

AU - Komeno, Yukiko

AU - Mitani, Kinuko

AU - Kishi, Yukiko

AU - Ogawa, Seishi

AU - Imataki, Osamu

AU - Chiba, Shigeru

AU - Kojima, Rie

AU - Hamaki, Tamae

AU - Sakiyama, Michiyo

AU - Kami, Masahiro

AU - Makimoto, Atsushi

AU - Tanosaki, Ryuji

AU - Takaue, Yoichi

AU - Hirai, Hisamaru

PY - 2005/2/15

Y1 - 2005/2/15

N2 - This prospective study evaluates the safety and efficacy of pravastatin for the treatment of chronic graft-versus-host disease (GVHD). We included 18 patients with refractory chronic GVHD. Oral pravastatin was started at 10 mg/day, and the dose was increased up to 40 mg/day in 4 weeks. This maximum dose was administered over 8 weeks. There were no severe adverse events caused by pravastatin. A clinical response was observed in the skin score in two patients, mouth score in five patients, eye score in two patients, liver score in three patients, platelet count score in one patient, and weight loss in two patients. The overall response rate was 28%. Immunophenotypic analyses showed that T-helper (Th) 1 cells were dominant in all but one patient before treatment and that the Th1/Th2 ratio tended to be lower in the responders than in the nonresponders. A randomized controlled trial is warranted to evaluate the efficacy of pravastatin against chronic GVHD.

AB - This prospective study evaluates the safety and efficacy of pravastatin for the treatment of chronic graft-versus-host disease (GVHD). We included 18 patients with refractory chronic GVHD. Oral pravastatin was started at 10 mg/day, and the dose was increased up to 40 mg/day in 4 weeks. This maximum dose was administered over 8 weeks. There were no severe adverse events caused by pravastatin. A clinical response was observed in the skin score in two patients, mouth score in five patients, eye score in two patients, liver score in three patients, platelet count score in one patient, and weight loss in two patients. The overall response rate was 28%. Immunophenotypic analyses showed that T-helper (Th) 1 cells were dominant in all but one patient before treatment and that the Th1/Th2 ratio tended to be lower in the responders than in the nonresponders. A randomized controlled trial is warranted to evaluate the efficacy of pravastatin against chronic GVHD.

KW - Chronic graft-versus-host disease

KW - Pravastatin

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=20044383914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20044383914&partnerID=8YFLogxK

U2 - 10.1097/01.TP.0000151001.64189.1D

DO - 10.1097/01.TP.0000151001.64189.1D

M3 - Article

C2 - 15699774

AN - SCOPUS:20044383914

VL - 79

SP - 372

EP - 374

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 3

ER -